- US-listed companies
- BioXcel Therapeutics, Inc.
- Income statement
BioXcel Therapeutics, Inc.BTAI
Market cap
$11.39M
P/E ratio
| 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | |
| Revenue | - | - | - | - | 0 | 1 | 2 |
| Revenue growth (%) | - | - | - | - | - | ||
| Cost of revenue | - | - | - | - | 0 | 1 | 2 |
| Research & development | 15 | 26 | 58 | 53 | 91 | 84 | 30 |
| Selling, general & administrative | - | - | - | - | 69 | 83 | 34 |
| Operating margin (%) | - | - | - | - | |||
| Operating income | -20 | -34 | -82 | -107 | -160 | -172 | -67 |
| Operating expenses | 20 | 34 | 82 | 107 | 160 | 173 | 70 |
| Net income | -19 | -33 | -82 | -107 | -166 | -179 | -60 |
| Net income margin (%) | - | - | - | - | |||
| Earnings per share | - | - | - | -4.05 | -5.92 | -6.15 | -23.51 |
| Diluted EPS | - | - | - | -4.05 | -5.92 | -6.15 | -23.51 |
| EBITDA | - | - | - |